The deal gives AZ the exclusive benefits of lucrative products such as byetta that are already on the market, as well as upcoming developments such as dapagliflozin (which, conveniently, was endorsed by US medical experts just last week).
And all for a reasonable price, too. Last month analysts thought the sale could be worth $6bn, so AZ seems to have done well – even allowing for all the add-ons.
Big pharma is no longer a simple game, and firms require brave CEOs who can carve out niche areas. As these two go their separate ways, it may lead to more strategic break-ups.